8-K: Neurogene Announces Positive Interim Results for Rett Syndrome Gene Therapy Trial

Neurogene reports positive interim efficacy data from the first four participants in the low-dose cohort of its NGN-401 gene therapy clinical trial for Rett syndrome, showing improvements in multiple key areas.

Summary

• Neurogene has released interim data from its Phase 1/2 clinical trial of NGN-401 gene therapy for Rett syndrome.
• The first four participants in the low-dose cohort showed a 2-point improvement on the Clinical Global Impression-Improvement (CGI-I) scale.
• All participants also demonstrated improvements in the Rett Syndrome Behavior Questionnaire (RSBQ), with improvements ranging from 28 to 52 percent.
• Participants showed gains in skills and developmental milestones, including hand function, language, and ambulation, which are not typically seen in the natural progression of Rett syndrome.
• The low-dose NGN-401 treatment was well-tolerated with a favorable safety profile.
• Neurogene has initiated an adolescent/adult cohort in the trial to assess the therapy's potential in a broader patient population.
• The company has also gained FDA alignment on its potency assay strategy and manufacturing scale-up plans.
• Neurogene does not plan to move forward with the NGN-101 CLN5 Batten disease gene therapy program due to a denied RMAT application.

Sentiment

Score: 8

Explanation: The document presents very positive interim clinical data, with significant improvements in patients and a favorable safety profile. The FDA alignment and expansion of the trial are also positive indicators. However, the discontinuation of the Batten disease program and a single SAE temper the overall sentiment slightly.

Positives

• The gene therapy showed significant improvements in multiple areas for all participants in the low-dose cohort.
• The treatment was well-tolerated with a favorable safety profile.
• The company has received FDA alignment on key aspects of the program, which is important for future development.
• The initiation of an adolescent/adult cohort expands the potential patient population for the therapy.
• The results show improvements beyond what is expected in the natural history of Rett syndrome.

Negatives

• One treatment-related serious adverse event (SAE) was reported in a high-dose participant, consistent with known risks of AAV gene therapy.
• The company has decided not to move forward with the NGN-101 CLN5 Batten disease gene therapy program due to a denied RMAT application.

Risks

• There is a risk of unexpected results or negative impacts to patients in the high-dose cohort or the adolescent/adult cohort.
• The company may not be able to report additional data on the predicted timeline.
• There are risks related to obtaining regulatory approval and commercializing the product.
• The company has a limited operating history and has incurred significant net losses since inception.
• There is a risk of reliance on third parties, contract manufacturers, and contract research organizations.

Future Outlook

Neurogene plans to expand the ongoing Phase 1/2 clinical trial, complete enrollment in the low-dose pediatric cohort, provide a regulatory update on the pivotal trial design, and announce additional clinical data. They also plan to advance one program into the clinic in 2025.

Management Comments

• Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene, stated that the data shows meaningful gains of skills and developmental milestones in core clinical domains of Rett syndrome, which are not expected to occur when compared to the natural history of Rett syndrome.
• Aleksandra Jacobs, M.D., Ph.D., Professor of Pediatric Neurology, noted that the totality of the outcomes shared with NGN-401 gene therapy have never been seen before in the treatment of Rett syndrome.

Industry Context

This announcement is significant in the context of rare neurological diseases, where there are often limited or no treatment options. The positive results for NGN-401 could position Neurogene as a leader in gene therapy for Rett syndrome, a devastating neurodevelopmental disease. The company's focus on a targeted approach to gene therapy using their EXACT technology is also noteworthy.

Comparison to Industry Standards

• The improvements observed in the NGN-401 trial, particularly the gains in developmental skills and milestones, are notable when compared to the natural history of Rett syndrome, where regression and loss of skills are typical.
• The 2-point improvement on the CGI-I scale is considered clinically meaningful, and the consistency of this result across all participants is a strong indicator of efficacy.
• While there are other companies developing treatments for Rett syndrome, the specific approach of NGN-401, using the full-length human MECP2 gene with the EXACT transgene regulation technology, differentiates it from other therapies.
• The safety profile of NGN-401 in the low-dose cohort appears favorable, which is crucial for gene therapy development, where safety concerns are paramount.
• The company's alignment with the FDA on potency assay strategy and manufacturing scale-up plans is a positive sign for the future commercialization of the therapy.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and regulatory progress.
• Patients and families affected by Rett syndrome will be encouraged by the potential of this therapy.
• Employees of Neurogene will be motivated by the positive results and the company's progress.
• The broader scientific and medical community will be interested in the advancements in gene therapy for neurological diseases.

Next Steps

• Expand the ongoing Phase 1/2 clinical trial to enroll a larger cohort of pediatric patients.
• Complete enrollment in the low-dose pediatric Cohort 1 (N=8) in the fourth quarter of 2024.
• Provide a regulatory update in the first half of 2025 regarding the pivotal trial design.
• Announce additional Phase 1/2 clinical data in the second half of 2025.
• Advance one program into the clinic in 2025.

Key Dates

Keywords

Rett syndrome, gene therapy, NGN-401, clinical trial, MECP2, FDA, AAV, neurological diseases, pediatric, biotechnology